Figure 1.

Expression of CD30 and CD25 on karpas299 cell surfaces evaluated by flow cytometric analysis and immunoreactivities of ¹¹¹In-HeFi-1 and ¹¹¹Indaclizumab with karpas299 cells. (A) Karpas299 cells strongly express both CD30 and CD25 on the cell surfaces. (B) Both ¹¹¹In-HeFi-1 and ¹¹¹In-daclizumab bound to karpas299 cells specifically, with maximum binding percentage more than 90%. ¹¹¹In-B3 did not bind to karpas299 cells. Both experiments were repeated once.